Advaxis Inc Cmn Stk (ADXS) 8.47 $ADXS
Phase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose-Escalation Cohort
GlobeNewswire - Tue Jul 26, 7:00AM CDT
Part A expansion and Part B now enrolling for AXAL in combination with durvalumab for the treatment of advanced, recurrent or refractory HPV-associated cervical cancer and head & neck cancer
ADXS: 8.47 (+0.13)
European Medicines Agency Committee Classifies Advaxis' Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product
GlobeNewswire - Mon Jul 18, 6:30AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that its lead Lm immunotherapy candidate, axalimogene filolisbac (AXAL), has been classified as an advanced-therapy medicinal product (ATMP) for the treatment of cervical cancer by the European Medicines Agency's Committee for Advanced Therapies (CAT).
ADXS: 8.47 (+0.13)
Advaxis to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
GlobeNewswire - Fri Jul 08, 7:00AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at Cantor Fitzgerald's 2nd Annual Healthcare Conference being held July 12-13, 2016 in New York, N.Y.
ADXS: 8.47 (+0.13)
Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer
GlobeNewswire - Wed Jun 08, 7:00AM CDT
FAWCETT study named to honor Farrah Fawcett, who passed away from HPV-associated anal cancer
ADXS: 8.47 (+0.13)
Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Durable complete response seen in a recurrent / metastatic cervical cancer patient previously treated with chemoradiation and systemic-dose chemotherapy plus bevacizumab
ADXS: 8.47 (+0.13)
Advaxis to Host Investor & Analyst Day on June 28, 2016
GlobeNewswire - Tue May 17, 7:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that they will host their annual Investor & Analyst Day, on Tuesday, June 28, 2016 at 1:30 PM EST in New York, NY.
ADXS: 8.47 (+0.13)
UPDATE - Advaxis to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 8:24AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 8.47 (+0.13)
Advaxis to Present at Jeffries 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 7:35AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 8.47 (+0.13)
FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the Food and Drug Administration (FDA) has granted Fast Track Designation for the company's immunotherapy product candidate ADXS-HER2 for patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma.
ADXS: 8.47 (+0.13)
Phase II Cervical Cancer Study with Advaxis' Axalimogene Filolisbac Selected for Poster Discussion Session at the 2016 ASCO Annual Meeting
GlobeNewswire - Mon Apr 25, 7:05AM CDT
Poster Discussion Sessions highlight the most clinically applicable and novel posters
ADXS: 8.47 (+0.13)
AACR Research Reception Featured Late-Breaking Poster on Lm Technology(TM) Platform
GlobeNewswire - Tue Apr 19, 8:05AM CDT
Reception included update on the Company's MINE program
ADXS: 8.47 (+0.13)
Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform
GlobeNewswire - Wed Apr 13, 7:00AM CDT
First biotechnology company to ever receive Vision of Hope Award
ADXS: 8.47 (+0.13)
Here's Why Advaxis Inc.'s Stock Roared Higher in March
George Budwell, The Motley Fool - Motley Fool - Tue Apr 12, 3:22PM CDT
What: Shares of the clinical-state biotech Advaxis gained over 50% last month, according to data from S&P Global Market Intelligence . The main catalyst behind this monstrous surge was the news that the company's midstage study for its...
ADXS: 8.47 (+0.13)
Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Study Evaluating ADXS-PSA Launches Third Dose-Escalation Cohort
ADXS: 8.47 (+0.13), MRK: 58.66 (unch)
Advaxis to Present at the 3rd Annual Jefferies Immuno-Oncology Summit
GlobeNewswire - Mon Apr 04, 8:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, will present at the 3rd Annual Jefferies Immuno-Oncology Summit on Friday, April 8 at the Boston Harbor Hotel.
ADXS: 8.47 (+0.13)
Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort
GlobeNewswire - Tue Mar 29, 6:05AM CDT
Study Commences Second Dose-Escalation Cohort
ADXS: 8.47 (+0.13)
UPDATE -- Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
GlobeNewswire - Wed Mar 23, 7:08AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host a Research Reception at the American Association for Cancer Research (AACR) Annual Meeting. The Research Reception, for which registration is required, will be held at 6:30 PM CT on April 18, 2016 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.
ADXS: 8.47 (+0.13)
Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
GlobeNewswire - Wed Mar 23, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host a Research Reception at the American Association for Cancer Research (AACR) Annual Meeting. The Research Reception, for which registration is required, will be held at 6:30 PM CT on April 18, 2016 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.
ADXS: 8.47 (+0.13)
Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research
GlobeNewswire - Mon Mar 21, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that data from a dose-escalation study of ADXS-HER2 in canine osteosarcoma (OSA) was published online March 18, 2016 in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).
ADXS: 8.47 (+0.13)
Advaxis to Present at Barclays Global Healthcare Conference
GlobeNewswire - Mon Mar 14, 6:17PM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it is scheduled to present on Wednesday, March 16, 2016 at 4:20 p.m. EDT at the 2016 Barclays Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida.
ADXS: 8.47 (+0.13)
Phase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose-Escalation Cohort
GlobeNewswire - Tue Jul 26, 7:00AM CDT
Part A expansion and Part B now enrolling for AXAL in combination with durvalumab for the treatment of advanced, recurrent or refractory HPV-associated cervical cancer and head & neck cancer
ADXS: 8.47 (+0.13)
European Medicines Agency Committee Classifies Advaxis' Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product
GlobeNewswire - Mon Jul 18, 6:30AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that its lead Lm immunotherapy candidate, axalimogene filolisbac (AXAL), has been classified as an advanced-therapy medicinal product (ATMP) for the treatment of cervical cancer by the European Medicines Agency's Committee for Advanced Therapies (CAT).
ADXS: 8.47 (+0.13)
Advaxis to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
GlobeNewswire - Fri Jul 08, 7:00AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at Cantor Fitzgerald's 2nd Annual Healthcare Conference being held July 12-13, 2016 in New York, N.Y.
ADXS: 8.47 (+0.13)
Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer
GlobeNewswire - Wed Jun 08, 7:00AM CDT
FAWCETT study named to honor Farrah Fawcett, who passed away from HPV-associated anal cancer
ADXS: 8.47 (+0.13)
Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Durable complete response seen in a recurrent / metastatic cervical cancer patient previously treated with chemoradiation and systemic-dose chemotherapy plus bevacizumab
ADXS: 8.47 (+0.13)
Advaxis to Host Investor & Analyst Day on June 28, 2016
GlobeNewswire - Tue May 17, 7:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that they will host their annual Investor & Analyst Day, on Tuesday, June 28, 2016 at 1:30 PM EST in New York, NY.
ADXS: 8.47 (+0.13)
UPDATE - Advaxis to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 8:24AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 8.47 (+0.13)
Advaxis to Present at Jeffries 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 7:35AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 8.47 (+0.13)
FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the Food and Drug Administration (FDA) has granted Fast Track Designation for the company's immunotherapy product candidate ADXS-HER2 for patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma.
ADXS: 8.47 (+0.13)
Phase II Cervical Cancer Study with Advaxis' Axalimogene Filolisbac Selected for Poster Discussion Session at the 2016 ASCO Annual Meeting
GlobeNewswire - Mon Apr 25, 7:05AM CDT
Poster Discussion Sessions highlight the most clinically applicable and novel posters
ADXS: 8.47 (+0.13)
AACR Research Reception Featured Late-Breaking Poster on Lm Technology(TM) Platform
GlobeNewswire - Tue Apr 19, 8:05AM CDT
Reception included update on the Company's MINE program
ADXS: 8.47 (+0.13)
Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform
GlobeNewswire - Wed Apr 13, 7:00AM CDT
First biotechnology company to ever receive Vision of Hope Award
ADXS: 8.47 (+0.13)
Here's Why Advaxis Inc.'s Stock Roared Higher in March
George Budwell, The Motley Fool - Motley Fool - Tue Apr 12, 3:22PM CDT
What: Shares of the clinical-state biotech Advaxis gained over 50% last month, according to data from S&P Global Market Intelligence . The main catalyst behind this monstrous surge was the news that the company's midstage study for its...
ADXS: 8.47 (+0.13)
Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Study Evaluating ADXS-PSA Launches Third Dose-Escalation Cohort
ADXS: 8.47 (+0.13), MRK: 58.66 (unch)
Advaxis to Present at the 3rd Annual Jefferies Immuno-Oncology Summit
GlobeNewswire - Mon Apr 04, 8:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, will present at the 3rd Annual Jefferies Immuno-Oncology Summit on Friday, April 8 at the Boston Harbor Hotel.
ADXS: 8.47 (+0.13)
Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort
GlobeNewswire - Tue Mar 29, 6:05AM CDT
Study Commences Second Dose-Escalation Cohort
ADXS: 8.47 (+0.13)
UPDATE -- Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
GlobeNewswire - Wed Mar 23, 7:08AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host a Research Reception at the American Association for Cancer Research (AACR) Annual Meeting. The Research Reception, for which registration is required, will be held at 6:30 PM CT on April 18, 2016 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.
ADXS: 8.47 (+0.13)
Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
GlobeNewswire - Wed Mar 23, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host a Research Reception at the American Association for Cancer Research (AACR) Annual Meeting. The Research Reception, for which registration is required, will be held at 6:30 PM CT on April 18, 2016 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.
ADXS: 8.47 (+0.13)
Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research
GlobeNewswire - Mon Mar 21, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that data from a dose-escalation study of ADXS-HER2 in canine osteosarcoma (OSA) was published online March 18, 2016 in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).
ADXS: 8.47 (+0.13)
Advaxis to Present at Barclays Global Healthcare Conference
GlobeNewswire - Mon Mar 14, 6:17PM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it is scheduled to present on Wednesday, March 16, 2016 at 4:20 p.m. EDT at the 2016 Barclays Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida.
ADXS: 8.47 (+0.13)
